Caribou Biosciences (NASDAQ:CRBU) Lowered to Sell Rating by Wall Street Zen

Key Points

• Wall Street Zen has downgraded Caribou Biosciences (NASDAQ:CRBU) from a "hold" rating to a "sell" rating.
• HC Wainwright reiterated a "buy" rating with a target price of $3.00, down from a previous target of $9.00.
• Recent trading data shows Caribou Biosciences opened at $1.98 and has a market cap of approximately $184.38 million.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued on Saturday.

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $3.00 target price (down from $9.00) on shares of Caribou Biosciences in a research report on Monday, April 28th. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $6.67.

Caribou Biosciences Stock Down 6.7%

NASDAQ:CRBU traded down $0.1250 during trading hours on Friday, hitting $1.7450. 503,046 shares of the stock were exchanged, compared to its average volume of 1,345,888. The company's 50 day moving average is $1.68 and its two-hundred day moving average is $1.25. The company has a market capitalization of $162.49 million, a P/E ratio of -0.98 and a beta of 2.55. Caribou Biosciences has a twelve month low of $0.66 and a twelve month high of $2.9995.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.35) EPS for the quarter, topping analysts' consensus estimates of ($0.40) by $0.05. The company had revenue of $2.67 million for the quarter, compared to analyst estimates of $1.64 million. Caribou Biosciences had a negative return on equity of 62.35% and a negative net margin of 1,800.93%. On average, equities research analysts expect that Caribou Biosciences will post -1.64 EPS for the current year.

Institutional Trading of Caribou Biosciences

A number of institutional investors have recently modified their holdings of the company. Next Capital Management LLC acquired a new stake in Caribou Biosciences during the 2nd quarter worth $25,000. Creative Planning purchased a new stake in Caribou Biosciences during the 2nd quarter worth about $25,000. Hudson Bay Capital Management LP purchased a new stake in shares of Caribou Biosciences during the 2nd quarter worth about $30,000. Russell Investments Group Ltd. boosted its holdings in Caribou Biosciences by 859.0% in the 4th quarter. Russell Investments Group Ltd. now owns 23,909 shares of the company's stock worth $38,000 after acquiring an additional 21,416 shares during the period. Finally, MetLife Investment Management LLC raised its position in shares of Caribou Biosciences by 60.0% during the 4th quarter. MetLife Investment Management LLC now owns 24,404 shares of the company's stock valued at $39,000 after acquiring an additional 9,148 shares in the last quarter. 77.51% of the stock is currently owned by institutional investors.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.